Efficacy and safety of sunitinib in Japanese patients with progressive, advanced/metastatic, well-differentiated, unresectable pancreatic neuroendocrine tumors: final analyses from a Phase II study

BACKGROUND: In an interim analysis of a Phase II trial in Japanese patients with pancreatic neuroendocrine tumors (panNETs), sunitinib demonstrated antitumor activity with an objective response rate (ORR) of 50% (95% confidence interval [CI], 21–79) and a median progression-free survival (PFS) of 16...

Descripción completa

Detalles Bibliográficos
Autores principales: Ito, Tetsuhide, Tori, Masayuki, Hashigaki, Satoshi, Kimura, Nobuyuki, Sato, Kazuo, Ohki, Emiko, Sawaki, Akira, Okusaka, Takuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452620/
https://www.ncbi.nlm.nih.gov/pubmed/30834940
http://dx.doi.org/10.1093/jjco/hyz009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452620/
https://www.ncbi.nlm.nih.gov/pubmed/30834940
http://dx.doi.org/10.1093/jjco/hyz009

Ejemplares similares